TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Need for total hip arthroplasty after PAO and hip arthroscopy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Erector Spinae Stiffness Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hallux Valgus Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-metatarsal Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiological Changes (Tibial Sesamoid Position)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum walking distance on treadmill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative myometry (QMT) scores of the upper and lower extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant Satisfaction with treatment #1
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant Satisfaction with treatment #2
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant Pain after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periprosthetic infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Need for ICU
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Healing of anal fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Levels of Interleukin-38 (pg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of Interleukin-36 gamma (pg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain measured by visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grip strength measured by hydraulic hand dynamometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of Tenofovir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower extremity functional scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of SBI Per Person-year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: AUC(t) at Steady-State Conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quick-Dash Abbreviated
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Objective Response Rate (CR and PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Successful result from the GFX procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Basic mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Iron levels in blood tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cleveland Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QoL) according to FIQL scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With Skin Erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Serum antibody titer targeting SARS-CoV-2 antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response rate according to 18F-FDG-PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile of Jusline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pharmacodynamic profile of Jusline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time Up and Go (TUG) test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Mild to Moderate Influenza Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Lesions With a Change in Radiologist's Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Qualitative Interpretations of CEUS in Diagnosing Kidney Malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of Qualitative Interpretations of CEUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative neurocognitive dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Migration of epidural catheter in centimetres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ovarian function parameters (FSH, LH, E2, T)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Patients' adherence to MMT
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of non-SLN(s) negative patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Paired Kappa Statistic for SBSS Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accumulated Energy Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: % of time within glucose target range (80-140 mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Treatment-Related Grade 3 or 4 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with anemia secondary to CKD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Recurrent Peptic Ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: VerifyNow P2Y12 PRU measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Atrial fibrillation within the first 7 days after ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of observed exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive for tuberculosis (TB)
Endpoint domain: Adverse events/effects
Primary endpoint: change in minimal and maximal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in limitation during sports
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change in quadriceps muscle cross-sectional area (CSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Anti-CS Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Montgomery Asberg Rating Scale (MADRS) for Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical impact of TEE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of TEE
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in vital signs during and following MHAA4549A administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in ECG findings during and following MHAA4549A administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stroke Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Diagnosis or exclusion of pulmonary embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: proportion of patients preferring modified meal versions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Embryo quality score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean quantity of alcohol consumed per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with less than a mean of one FMF attack per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported health state
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diagnosis of procedure-related pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to objective progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rates (PSA and objective)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 2.0
Endpoint domain: Adverse events/effects
Primary endpoint: Parasympathetic activity measured by heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in PBC-40 Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Disease evaluation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PET negativity after induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HgA1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in resting blood flow and neural activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants Achieving Antibody Level ≥0.35μg/mL After Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Antibody Concentration (GMC) After Vaccination in 13vPnC Groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improved bowel preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of complications after the operation
Endpoint domain: Adverse events/effects
Primary endpoint: Development of severe pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Transvaginal biomechanical maps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transvaginal electromyography maps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary Lcn2/creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Brain GSH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Wound Disruption and/or Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Body weight management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Insomnia Severity Index Score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: prevalence of uterine niche
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Post Procedure Discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Duration of Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endogenous erythropoietin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Vaccination uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Subjects Who Passed the Voiding Trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area Under the Curve of motor function based on finger tapping scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymphocyte subset analysis (CD4+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: closure rate of PDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Keratometry measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin Lispro Area Under the Plasma Concentration Curve Zero to 10 Hours (AUC[0-10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Positive skin prick test response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in symptom burden
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Urinary 2,8-dihydroxyadenine Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensibility and specificity of lung sonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oral morphine systemic exposure (AUC 0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PTSD Symptom Scale (PSS-I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Mean Number of Stress Incontinence Episodes Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Placebo-corrected Change From Baseline For QTcF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient perception of overall effectiveness, acceptability, and usability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptom prevalence and severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Level of Carboxyterminal Cross-linked Telopeptide of Type I Collagen (CTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Levels of Tartrate-resistant Acid Phosphatase 5b Isoenzyme (TRAcP5b)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Levels of Bone-specific Alkaline Phosphatase (BAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Enrichment of Bicarbonate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comprehension of disease characteristics
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to loss of efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change of pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient retention in care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Significant recurrence of Hepatitis C
Endpoint domain: Adverse events/effects
Primary endpoint: Development of contracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of patients upstaged to Stage IV disease
Endpoint domain: Mortality/survival
Primary endpoint: Area under the plasma concentration-time curve from time zero until 24 hours (AUC0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough plasma concentration observed at the end of the dosing interval (Ctrough)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in sweat chloride concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in percent predicted FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: fMRI patterns of connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent in-segment diameter stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average Plasma Concentration (Cav)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total energy expenditure (kcal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin Irritation Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Sensitization Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of number of bowel movements at 1 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of number of bowel movements at 2 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Motor testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Success rate of fiberoptic bronchoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hot Flash Score (Frequency and Severity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in ApoA1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of regression of CIN1 to normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Caregiver Assistive Technology Outcome Measure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in blister fluid total and differential leukocyte numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Modification of MR parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: brachial artery flow-mediated dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: asthma free days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Exogenous carbohydrate oxidation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycogen utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Unexpected Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Expected AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Visual Index Ichthyosis Severity (VIIS) Scaling Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in self-reported cognitive difficulties
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Colon preparation quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Residual mitral valve regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mitral valve coaptation area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Haptoglobin at 3 months after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Lactate dehydrogenase at 3 months after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of NT-proBNP at 3 months after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of effect of treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of perioperative hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Inflammatory Lesion Count Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of adverse events related to the investigational drug
Endpoint domain: Adverse events/effects
Primary endpoint: Subcutaneous fat layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Minimum Concentration (Cmin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abortion Rate (AR)
Endpoint domain: Mortality/survival
Primary endpoint: Maternal complications rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: IUD Expulsion Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Establishment of an allograft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Motor Activity Log (MAL) Arm Use Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Acute and Grade 2 or Higher Radiation-related Skin Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Early Deep Vein Thrombosis incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Quality of life (QOL) according to FACT-L
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of bleeding lesions detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced narrowing of heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pre- and Post-treatment Ambulatory Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in lower extremity skeletal muscle perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes